Autumn 2026
Beyond gravity — What happens when biotech leaves Earth?
The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies. This issue features a list of eight venture capital firms to watch in 2026. Other exciting topics include the treatment of epilepsy, targeted protein degradation, and Sanofi’s way into in vivo CAR-T therapy.
The autumn issue of European Biotechnology magazine asks what happens when biotech leaves Earth. Our cover story explores how microgravity could help researchers study disease, improve drug formulations and develop new ways to manufacture medicines.
Back on Earth, this issue examines whether Europe can turn its scientific strengths into global biotech companies. We speak with argenx CEO Karen Massey about the company’s next chapter and with investor Thomas Strüngmann about building successes that support the next generation.
Our two specials explore advances in autoimmunity and inflammation, and the changing demands on Europe’s CROs and CDMOs.
Further topics in this issue:
- Deep dive: Gene therapies for inherited hearing loss
- Watchlist: Six Spanish biotech startups to watch
- Can Europe benefit from the U.S.–China biotech split?
- What it takes to raise capital in today’s market
- Why “AI biotech” is losing its meaning for investors
- The laboratory bottleneck in AI drug discovery
Special: Autoimmunity & inflammation
- How cancer research is opening new approaches to autoimmune disease
- Interview: Immunic CEO Erik Lundgren on developing a treatment for multiple sclerosis
Special: CRO & CDMO
- How Europe’s outsourcing model is changing
- WuXi AppTec’s expansion in Europe
- Making technology transfer work
- Why European CDMOs are expanding in the U.S.
- How the ADC boom is driving CDMO investment
- Why complex European trials are increasing demand for CROs
The issue also includes the second edition of life, the bioRN Life Science Cluster magazine, as a supplement.
